Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2009

View Archived Issues

Novel tools for post-transplant tacrolimus dose optimization reported

Banyu describes 4-sulfonylpiperidine derivatives for the treatment of diabetes

Kitasato Institute and Kyowa Hakko Kirin claim novel KB-3346-5 substances as antiinfective agents

Improved early virologic response rates seen with GI-5005 in phase II HCV study

Preclinical data on phase I antiangiogenic mAb, PF-03446962, presented

AEZS-126, a new orally bioavailable PI3K inhibitor shows preclinical antitumor activity

Intravitreal viral delivery of VEGF antagonist developed as therapy for ocular neovascularization

Intarcia completes enrollment in phase Ib clinical study of ITCA-650 in type 2 diabetes

Novel multitargeted kinase inhibitor displays potent antitumor activity in preclinical cancer models

Choongwae patents GSK-3beta inhibitors for the treatment of Alzheimer's disease

Novel PI3K inhibitors for cancer treatment jointly patented by Genentech and Roche

Antisense begins pivotal phase III trabedersen trial in aggressive brain tumors

Avila Therapeutics' novel agent AVL-181 silences HCV protease activity

Peregrine presents preliminary phase II bavituximab data in breast cancer

Pharmasset and Roche dose first patient in phase IIb clinical trial of HCV drug R-7128

CHMP recommends approval of pediatric formulation of Tracleer in PAH

Clinical study shows anti-HCV efficacy of NIM-811 with peginterferon

Janssen receives Japanese approval to market Risperdal Consta for schizophrenia

European Commission grants Wyeth marketing authorization for Conbriza

Novel Aurora kinase inhibitors claimed by Bayer for cancer treatment

FDA accepts for review Theravance's complete response for telavancin in cSSSI

FDA grants orphan drug designation to Pharming's Prodarsan for Cockayne syndrome

Phase III Nexavar trial in advanced melanoma does not meet primary endpoint

Phase II GSK-1838262 results reported for pain in diabetic peripheral neuropathy

Sepracor reports preliminary phase III Omnaris results in allergic rhinitis

Once-daily antiepileptic Zebinix approved in the European Union

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...